This article compiles data on cosmetic supervision as well as sampling inspections conducted within China and information on updates for June 2025.
Cosmetic Supervision and Sampling Inspection Data
In June 2025, the Beijing Municipal Medical Products Administration issued the 2025 Second Bulletin on the Quality and Safety of Cosmetics from Supervision and Sampling Inspection, in which six batches of products were found to be non-compliant with regulations. The Ningxia Hui Autonomous Region Medical Products Administration released the “Notice on the Supervision and Inspection of Four Cosmetic Manufacturing Enterprises,” indicating that two enterprises were found to have general deficiencies, while the other two were not in production.
1. Beijing Municipal Medical Products Administration 2025 Second Bulletin on the Quality and Safety of Cosmetics from Supervision and Sampling Inspection (Announcement [2025] No. 15)
On June 4, 2025, the Beijing Municipal Medical Products Administration issued this announcement. In 2024, the Administration organized a supervision and sampling inspection of the cosmetic production sector (including registrants, filers, and domestic responsible persons) and online business operations across the city. Six batches of products were found to be non-compliant with regulations. The non-compliant products included acne treatment essence, hair dye cream, and hair dye paste. The items that failed to meet regulatory standards included excessive salicylic acid content and the detection of prohibited ingredients such as chlorpheniramine. The relevant entities have taken necessary control measures for the non-compliant cosmetics, and the non-compliant products have been investigated and dealt with in accordance with applicable laws and regulations.
https://yjj.beijing.gov.cn/yjj/xxcx/zlgg/hzp72/743636001/index.html
2. Ningxia Hui Autonomous Region Medical Products Administration Releases Notification on the Supervision and Inspection of Four Cosmetic Manufacturers
On June 11, 2025, the Ningxia Hui Autonomous Region Medical Products Administration issued a notification titled “Notice on the Supervision and Inspection of Four Cosmetic Manufacturing Enterprises.” According to the notice, on May 14, 20, and 22, 2025, the Administration organized inspections of four cosmetic manufacturers. The inspections revealed that two of the enterprises had general deficiencies, while the remaining two were not in production at the time of inspection.
http://nxyjj.nx.gov.cn/yp/ggtg_37855/202506/t20250611_4931399.html
Information Sharing
1. On June 9, 2025, the Jiangxi Medical Products Administration issued a notice titled “Notice on Further Strengthening the Investigation and Handling of Clues Related to Illegal Online Cosmetic Operations.” The notice aims to intensify regulatory efforts over online cosmetic sales and crack down on illegal activities in the online cosmetics market.
Moving forward, the Jiangxi Administration will organize local authorities to promptly and effectively handle leads on unlawful online operations, strengthen law enforcement, and focus on cracking down on violations such as the sale of unregistered or unfiled cosmetics, counterfeit cosmetics, cosmetics produced without a license, and products involved in “one approval number for multiple products” practices. Targeted regulatory measures will be implemented to address frequent and high-risk issues, in order to prevent and mitigate cosmetic quality and safety risks in a timely manner.
2. On June 16, 2025, the Guangzhou Municipal Administration for Market Regulation issued the “Notice on the Cancellation of Cosmetic Manufacturing Licenses (Fourth Batch of 2025).” In accordance with the Administrative Licensing Law of the People’s Republic of China, the Cosmetics Supervision and Administration Regulations, and the Measures for the Supervision and Administration of Cosmetics Production and Operation, the cosmetic manufacturing licenses of eight enterprises have been lawfully and officially canceled. All cancellations were initiated voluntarily by the enterprises. As of now, the Administration has publicly released two batches of cancellation information in 2025, involving a total of 29 enterprises. Two additional batches of cancellation data have not yet been disclosed to the public.
3. On June 23, 2025, the Zhejiang Provincial Medical Products Administration reported that the Putuo District Bureau of Zhoushan City has successfully completed the 2025 annual cosmetic sampling task. Closely aligned with the province’s special campaign on the safety of pharmaceuticals used and sold by “three-small” entities (small workshops, small beauty salons, and small retail outlets), the bureau carried out targeted and efficient sampling operations.
A total of 20 batches of cosmetic samples were collected, including 10 batches from “three-small” cosmetic business entities. This year’s sampling efforts were risk-focused, with products selected based on factors such as raw material usage, production processes, and consumer usage frequency. Special attention was given to products prone to safety issues or those with high public concern.
The sampling initiative was deeply integrated with the broader campaign targeting “three-small” pharmaceutical operations. In addition to collecting samples, the bureau conducted comprehensive inspections of product sourcing, regulatory compliance, labeling, and advertising claims within these businesses. Irregularities were promptly identified and rectified, and enterprises were urged to fulfill their primary responsibilities in ensuring product quality and safety.
About CIRS
The CIRS cosmetic team is dedicated to ensuring that cosmetic products meet stringent global regulatory standards. It can provide one-stop services covering the whole life-cycle of a personal care product, which includes cosmetic ingredient development, physical/chemical tests, toxicological tests (in vivo & in vitro), efficacy studies (in vivo & in vitro), ingredient registration, and product registration.
About CIRS Biotech
CIRS Biotech is a professional third-party testing organization in Hangzhou, China, established by CIRS Testing from CIRS Group and Professor Jianxin Wu’s team from China Pharmaceutical University in 2022. CIRS Biotech is providing scientific supports of cosmetic efficacy and claims for cosmetic ingredients and products. The services include in-vitro research of efficacy for cosmetic ingredients and products, in-depth research on in-vitro study method, R&D support, etc.
Cosmetic services in China:
- China Cosmetic Registration and Filing;
- China New Cosmetic Ingredient Registration and Filing;
- China Cosmetic Ingredient Quality and Safety Information Code Application (NMPA Code);
- China Cosmetics Clinical Efficacy Evaluation;
- In-vitro Efficacy Evaluation
- In-vitro Safety Evaluation
- China Cosmetic Safety Assessment Report;
- China Toothpaste Filing;
- China Disinfectant Notification; and
- China Cosmetic Formula/Label/Claim Review
If you need any assistance or have any questions, please get in touch with us via kexinbio@cirs-group.com.
Contact Us
Quick Navigation